spironolactone has been researched along with Adrenocortical Carcinoma in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression." | 5.72 | Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022) |
| "We report a rare case of adrenocortical carcinoma." | 5.32 | Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma. ( Azizlerli, H; Kapran, Y; Kurtulmus, N; Yarman, S, 2004) |
| "Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression." | 1.72 | Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022) |
| "We report a rare case of adrenocortical carcinoma." | 1.32 | Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma. ( Azizlerli, H; Kapran, Y; Kurtulmus, N; Yarman, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Haberbosch, L | 1 |
| Maurer, L | 1 |
| Sandforth, A | 1 |
| Wernicke, C | 1 |
| Spranger, J | 1 |
| Mai, K | 1 |
| Jumpertz von Schwartzenberg, R | 1 |
| Kurtulmus, N | 1 |
| Yarman, S | 1 |
| Azizlerli, H | 1 |
| Kapran, Y | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
3 other studies available for spironolactone and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Male; M | 2022 |
Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aldosterone; Diuretics; Female; Histocyto | 2004 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |